Antitumor Effects of Conditional Replication Adenovirus in Combination with Cisplatin on Lung Cancer ()
Abstract
Object:
To explore the therapeutic effects and therapeutic mechanisms of Conditional
Replication Adenovirus(CRAd) in combination with cisplatin on lung cancer
cells. Methods: Using MTS / PMS assay, in
vitro cell inhibition assay was performed to detect the cell viability of
two lung cancer cell lines, NCI-H292 and NCI-H661. PCR was employed to detect
the Coxsackie receptor(CAR) expression of cancer cells. The in vivo anti-tumor effect of CRAd and
cisplatin was evaluated using a subcutaneous mouse model. Results: The CRAd
with cisplatin is superior to the use of cisplatin or CRAd viruse alone on the
suppression of lung cancer cell growth. The mechanism of inhibition is
associated with the increased CAR expression. Conclusion: The application of
CRAd in combination with cisplatin could play a better therapeutic effect on
lung cancer cell growth inhibition.
Share and Cite:
Y. Liu and Y. Huang, "Antitumor Effects of Conditional Replication Adenovirus in Combination with Cisplatin on Lung Cancer,"
Engineering, Vol. 4 No. 10B, 2012, pp. 163-164. doi:
10.4236/eng.2012.410B042.
Conflicts of Interest
The authors declare no conflicts of interest.
References
[1]
|
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 : 62(1):10-29.
|
[2]
|
Arany I,Safirstein RL.Cisplatin nephrotoxicity.Semin NePhlol. 2003; 23 (5): 460 -464.
|
[3]
|
Uyama N,Hatano E,Maetani Y,et al. Efficacy and toxicity of transcatheter arterial chemoembolization with cisplatin suspended inlipiodol for unresectable hepatocellularearcinoma.GanTo Kagaku Ryoho,2008;35(5):775-780
|
[4]
|
Chu RL,Post DE,Khuri FR,et al.Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Ca-neer.Clinical Cancer Research .2004; 10(16): 5299- 5312.
|
[5]
|
Honda T, Saitoh H,Masuko M,et al.The coxsackievirus adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain [J] .Brain Res Mol Brain Res,2000,77:19-8.
|